IL2 and cancer: Thus, there is a substantial interest in γδ T cells in the context of immunotherapeutic strategies and several pilot studies have described a partial success of γδ T cell-based immunotherapy in different types of cancer after the application of aminobisphosphonates (n-BP) or PAgs plus IL-2 in vivo or after repetitive transfer of in vitro expanded Vγ9Vδ2 T cells [27,28].